Korea’s Financial Regulator To Investigate Celltrion CEO On Alleged Insider Trading, Stock Manipulation
This article was originally published in PharmAsia News
The Financial Services Commission has asked state prosecutors to investigate Celltrion CEO Seo Jung-jin over alleged stock price manipulation, which is bad news for Seo who is looking to sell his stake in the biosimilars company.
You may also be interested in...
Hospira’s Inflectra becomes the first biosimilar monoclonal antibody to be authorized in Europe – but pricing and overcoming doctors’ skepticism looks like the key to real EU success.
Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.
Phase III studies testing Dupixent in moderate-to-severe asthma were largely positive, but subgroup details raise questions about how it will compete against biologics targeting the IL-5 pathway. Some experts urge comparison trials to inform physicians' decisions about long-term use.